Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival …
The immunology of hormone receptor positive breast cancer
J Goldberg, RG Pastorello, T Vallius, J Davis… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The
main focus of ICB has been on reinvigorating the adaptive immune response, namely …
main focus of ICB has been on reinvigorating the adaptive immune response, namely …
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani… - The lancet …, 2018 - thelancet.com
Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy
while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative …
while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative …
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer… - Journal of clinical …, 2012 - ascopubs.org
Purpose The exact definition of pathologic complete response (pCR) and its prognostic
impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor response …
impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor response …
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
Purpose Preclinical data suggest a contribution of the immune system to chemotherapy
response. In this study, we investigated the prespecified hypothesis that the presence of a …
response. In this study, we investigated the prespecified hypothesis that the presence of a …
[HTML][HTML] Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
BACKGROUND: Pathologic complete response (pCR) is a surrogate end-point for prognosis
in neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to report summary …
in neoadjuvant chemotherapy (NAC) for breast cancer. We aimed to report summary …
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
Purpose To measure residual disease after neoadjuvant chemotherapy in order to improve
the prognostic information that can be obtained from evaluating pathologic response …
the prognostic information that can be obtained from evaluating pathologic response …
Response-guided neoadjuvant chemotherapy for breast cancer
G von Minckwitz, JU Blohmer, SD Costa… - Journal of Clinical …, 2013 - ascopubs.org
Purpose We investigated disease-free survival (DFS) and overall survival (OS) after
response-guided neoadjuvant chemotherapy in patients with early breast cancer. Patients …
response-guided neoadjuvant chemotherapy in patients with early breast cancer. Patients …
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult …
Chemotherapy-induced neutropaenia is a major risk factor for infection-related morbidity
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …
and mortality and also a significant dose-limiting toxicity in cancer treatment. Patients …